Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,012 across all filing types
Latest filing 2019-12-20 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
独立董事关于第五届董事会第一次会议相关事项的独立意见
Board/Management Information Classification · 100% confidence The document is an independent opinion from the independent directors regarding the appointment of senior management at 康芝药业股份有限公司. It references compliance with company law, stock exchange listing rules, and company articles of association. The content focuses on the legality and qualifications of the appointed senior management personnel, including the president, vice presidents, financial director, and board secretary. There is no financial data, earnings information, or report publication mentioned. The document is clearly related to board/management information, specifically announcements about changes in senior management. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication or a certification letter, so it does not fall under RPA or RNS.
2019-12-20 Chinese
第五届监事会第一次会议决议公告
Board/Management Information Classification · 100% confidence The document is an announcement of the resolution from the first meeting of the fifth Supervisory Board of Kangzhi Pharmaceutical Co., Ltd. It includes the election of the Supervisory Board Chairman and a brief biography of the elected chairman. The content focuses on board/management changes and appointments, not on financial results, audit, or other report types. The document length is short (1068 characters), and it is clearly a formal announcement of a management/board decision. Therefore, it fits the category of Board/Management Information (MANG).
2019-12-20 Chinese
2019年第一次临时股东大会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality and validity of the procedures, attendance, and voting results of a company's 2019 first extraordinary general meeting (临时股东大会). It details the convening, attendance, voting procedures, and results of the meeting, including election of board members and supervisors. The document is not a report of financial results, audit, or management discussion, but a legal opinion on the shareholder meeting process and resolutions. It is not a report publication announcement or a brief notice but a substantive legal opinion document. This type of document corresponds to a Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially confirms the voting results and legality of the shareholder meeting resolutions.
2019-12-19 Chinese
2019年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a resolution announcement for the 2019 first extraordinary general meeting (临时股东大会决议公告) of 康芝药业股份有限公司. It details the meeting date, voting methods, attendance, and the results of various board and supervisory committee elections. It includes voting results and legal opinions confirming the validity of the meeting and resolutions. There is no financial data or report content, only the official announcement of voting results and meeting resolutions. The document length is 3871 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2019-12-19 Chinese
关于召开2019年第一次临时股东大会通知的提示性公告
AGM Information Classification · 95% confidence The document is a detailed announcement regarding the convening of the 2019 first extraordinary general meeting of shareholders for 康芝药业股份有限公司. It includes information about the meeting date, voting methods (both onsite and online), agenda items focusing on the election of board directors and supervisors, registration procedures, and proxy voting instructions. The content is procedural and preparatory for a shareholder meeting, not the meeting materials themselves or the voting results. It does not contain financial statements, audit information, or earnings data. The document is not a report but a notice about the meeting and how shareholders can participate and vote. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during or related to the Annual General Meeting or other shareholder meetings.
2019-12-16 Chinese
关于公司2018年股票期权激励计划部分股票期权注销完成的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the cancellation of part of a stock option incentive plan for certain employees due to their departure or contract termination. It details the number of stock options cancelled and the updated figures after cancellation. The document is a formal announcement related to changes in the company's stock option plan, which is a capital structure change. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length is short and it is not a report publication announcement or certification. Hence, the classification is SHA with high confidence.
2019-12-16 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.